Cargando…
Recent advances in T-cell engineering for use in immunotherapy
Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific...
Autores principales: | Sharma, Preeti, Kranz, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031132/ https://www.ncbi.nlm.nih.gov/pubmed/27703664 http://dx.doi.org/10.12688/f1000research.9073.1 |
Ejemplares similares
-
Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges
por: Jin, Jing, et al.
Publicado: (2020) -
Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy
por: Wang, Fengshuo, et al.
Publicado: (2022) -
Advances in Engineering Cells for Cancer Immunotherapy
por: Xu, Xiao, et al.
Publicado: (2019) -
Soluble T Cell Receptor Vβ Domains Engineered for High-Affinity Binding to Staphylococcal or Streptococcal Superantigens
por: Sharma, Preeti, et al.
Publicado: (2014) -
Recent advances in cancer immunotherapy
por: Sun, Qiang, et al.
Publicado: (2021)